Holen Sie sich die Stockscreener-App
6.07
2.19%
0.13
Vorhandelsmarkt:
6.08
0.010
+0.16%
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT Insight - GuruFocus
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat
Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat
XERS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript - Insider Monkey
XERS Earnings History & Surprises | EPS & Revenue Results | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
Xeris Biopharma Holdings, Inc.Common Stock (NQ: XERS - The Chronicle-Journal
Xeris Biopharma Q4 2025 Earnings Call Transcript - MarketBeat
Xeris Biopharma Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results - MarketBeat
Beth Hecht 10b5-1 sales reported for XERS (NASDAQ: XERS) - Stock Titan
XERS: Achieved first annual net profit and 43.7% revenue growth, led by Recorlev's strong performance - TradingView
Xeris Biopharma (NASDAQ: XERS) outlines endocrine and neuro focus - Stock Titan
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highli - GuruFocus
Today's Analyst Update: XERS Rating Reiterated at Buy by HC Wain - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Receives Buy Rating from HC Wainwright - MarketBeat
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's What Happened - MarketBeat
Earnings call transcript: Xeris Biopharma’s Q4 2025 earnings beat estimates, stock surges - Investing.com Australia
Xeris Biopharma Q4 Earnings Call Highlights - Yahoo Finance
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
XERS Projects Strong Growth for FY26 with Significant Revenue In - GuruFocus
Xeris (XERS) Sees Strong Q4 Revenue Growth - GuruFocus
(XERS) Xeris Biopharma Expects 2026 Total Revenue Range $375M to $390M, vs. FactSet Est of $368M - marketscreener.com
Earnings Flash (XERS) Xeris Biopharma Holdings, Inc. Reports Q4 Revenue $85.8M, vs. FactSet Est of $82.2M - marketscreener.com
Xeris Bi - Bitget
Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance - Investing.com
Xeris Biopharma: Q4 Earnings Snapshot - marketscreener.com
Xeris Biopharma Reports Record Performance for Q4 and Full Year 2025 - TradingView
XERS: Record 2025 revenue and profitability set the stage for over 30% growth in 2026 - TradingView
Record 2025 results as Xeris Biopharma (XERS) guides for 30%+ 2026 growth - Stock Titan
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance - Business Wire
A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev Exclusivity - Yahoo Finance
Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040 - Sahm
Xeris Biopharma (NASDAQ:XERS) Trading Down 8.3%Should You Sell? - MarketBeat
Why Are Shares Of Xeris Biopharma Falling Friday? - Benzinga
Xeris Biopharma Holdings Enters Oversold Territory (XERS) - Nasdaq
Xeris Pharmaceuticals (XERS) Set to Announce Q4 Earnings with St - GuruFocus
A Peek at Xeris Biopharma Holdings's Future Earnings - Benzinga
Pullback Watch: Can Xeris Biopharma Holdings Inc keep up with sector leadersJuly 2025 PreEarnings & Low Volatility Stock Suggestions - baoquankhu1.vn
Xeris Biopharma Sues Torrent Pharmaceuticals, Somerset Therapeutics Over Recorlev Patents - marketscreener.com
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a 65% Potential Upside for Investors - DirectorsTalk Interviews
Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit - marketscreener.com
Xeris Biopharma (XERS) Sues Over Recorlev Patent Dispute - GuruFocus
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event | XERS SEC FilingForm 8-K - Stock Titan
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit - The Chronicle-Journal
Xeris Biopharma Holdings Inc (referred to as Xeris) announced today that the company will firmly uphold and defend its intellectual property rights related to the innovative drug Recorlev. - Bitget
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Xeris Biopharma (XERS) officer logs tax-related share withholding move - Stock Titan
Risks Report: Will Xeris Biopharma Holdings Inc benefit from seasonalityPortfolio Return Summary & Community Verified Watchlist Alerts - baoquankhu1.vn
Xeris Biopharma (XERS) to Release Earnings on Monday - Defense World
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a Promising 65% Potential Upside - DirectorsTalk Interviews
Can Xeris Biopharma Holdings Inc. stock hit analyst price targetsJuly 2025 Drop Watch & Fast Gain Swing Trade Alerts - mfd.ru
Is Xeris Biopharma Holdings Inc. stock a smart retirement pickJuly 2025 Summary & Risk Managed Trade Strategies - mfd.ru
What’s the RSI of Xeris Biopharma Holdings Inc. stockWeekly Gains Summary & Safe Entry Trade Reports - mfd.ru
Xeris Biopharma (NASDAQ:XERS) Trading Down 9.3%Should You Sell? - MarketBeat
XERS Crosses Below Key Moving Average Level - Nasdaq
Will Xeris Stock Revisit Its 52-week High? - RTTNews
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by CenterBook Partners LP - MarketBeat
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 - The Chronicle-Journal
What margin trends mean for Xeris Biopharma Holdings Inc. stockJuly 2025 Final Week & AI Optimized Trade Strategies - mfd.ru
Can Xeris Biopharma Holdings Inc. keep up with sector leadersPrice Action & AI Forecast for Swing Trade Picks - mfd.ru
Xeris Biopharma Holdings (XERS) Investor Outlook: Aiming for a 61% Upside with Strong Buy Ratings - DirectorsTalk Interviews
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):